Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06726304 shows robust antitumor growth activity. PF-06726304 is an effective and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 (Kis: 0.7 and 3.0 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 33.00 | |
2 mg | In stock | $ 46.00 | |
5 mg | In stock | $ 74.00 | |
10 mg | In stock | $ 127.00 | |
25 mg | In stock | $ 293.00 | |
50 mg | In stock | $ 531.00 | |
100 mg | In stock | $ 768.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 81.00 |
Description | PF-06726304 shows robust antitumor growth activity. PF-06726304 is an effective and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 (Kis: 0.7 and 3.0 nM, respectively). |
Targets&IC50 | EZH2 (Y641N):3.0 nM (ki), EZH2 (WT):0.7 nM (ki) |
In vitro | PF-06726304 suppresses the proliferation of Karpas-422 cells that harbor wild-type EZH2 (IC50: 25 nM). PF-06726304 suppresses H3K27me3 in Karpas-422 (IC50: 15 nM) [1]. |
In vivo | In a subcutaneous Karpas-422 xenograft model, PF-06726304 (200 and 300 mg/kg; BID for 20 days) suppresses tumor growth and causes robust modulation of downstream biomarkers[1]. |
Molecular Weight | 446.33 |
Formula | C22H21Cl2N3O3 |
CAS No. | 1616287-82-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (33.61 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06726304 1616287-82-1 Chromatin/Epigenetic Histone Methyltransferase antitumor H3K27me3 Karpas-422 PF 06726304 EZH2 inhibit Inhibitor Y641N PF06726304 inhibitor